The company’s recent announcements highlight its commitment to advancing patient care, particularly in oncology and molecular diagnostics Bio-Rad Laboratories, a global leader in life sciences and clinical diagnostics, has made…

The company’s recent announcements highlight its commitment to advancing patient care, particularly in oncology and molecular diagnostics

Bio-Rad Laboratories, a global leader in life sciences and clinical diagnostics, has made significant strides in 2024, launching numerous cutting-edge products and achieving key regulatory milestones. The company’s recent announcements highlight its commitment to advancing patient care, particularly in oncology and molecular diagnostics.

Key Highlights from Bio-Rad’s 2024 Portfolio:

• Oncology Assay Updates:
  Bio-Rad achieved IVDR Class C certification for its QXDx BCR-ABL %IS Kit (IVD/CE-IVD), designed to monitor Chronic Myeloid Leukemia (CML) patients using Droplet Digital PCR (ddPCR) technology. The company also announced strategic collaborations in molecular residual disease (MRD) detection and circulating tumour DNA (ctDNA) analysis, furthering its mission to enhance cancer biomarker detection.
• New Product Launches in Gene Therapy:
  In February, Bio-Rad introduced the Vericheck ddPCR Replication Competent Lentivirus Kit and the Replication Competent AAV Kit, providing precise quantification solutions for safe cell and gene therapy production.
• Expanded Tools for Flow Cytometry and Cell Research:
  The company released eight new Annexin V StarBright Dyes in August, offering researchers an expanded range of fluorophores for apoptosis detection. Bio-Rad also launched 32 new StarBright dyes for multicolour flow cytometry, enhancing flexibility for immunological studies.
• Innovations in Single-Cell and Digital PCR Technology:
  Bio-Rad unveiled the ddSEQ Single-Cell 3′ RNA-Seq Kit with Omnition v1.1 software, enabling advanced single-cell transcriptomic research. It also debuted the ddPLEX ESR1 Mutation Detection Kit, a multiplexed assay for oncology applications, in April.
• Rare Cell Capture Advancements:
  With the launch of Celselect Slides 2.0 in June, Bio-Rad improved rare cell and circulating tumour cell (CTC) capture, compatible with its Genesis Cell Isolation System.
• Notable Study Publication:
  A study published in Nature Communications demonstrated Bio-Rad’s SpyLock technology for accelerating bispecific antibody development and validation, a pivotal tool for therapeutic discovery.
• Regulatory Milestones in Food Safety:
  The dd-Check STEC Solution became the first ddPCR method approved by AOAC INTERNATIONAL for confirming virulence genes from Shiga toxin-producing E. coli, cementing Bio-Rad’s role in ensuring food safety.

These accomplishments underscore Bio-Rad’s dedication to providing innovative scientific research and diagnostics tools, setting a benchmark for technological excellence in the life sciences industry.